Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys

  title={Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys},
  author={Aikaterini Thanou and Joan Tenenbaum Merrill},
  journal={Nature Reviews Rheumatology},
Despite rapid accumulation of knowledge about complex immune dysregulation in systemic lupus erythematosus (SLE) and major primary lupus syndromes, and a plethora of promising new treatments reaching preclinical and early clinical studies, advanced-phase trials of new biologic agents have repeatedly failed to achieve their clinical end points. It is possible that none of these agents work, but the accuracy of this suggestion is as unclear as the case for efficacy, owing to issues in the design… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
20 Citations
96 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 20 extracted citations


Publications referenced by this paper.
Showing 1-10 of 96 references

10 things to know about lupus activity

  • A. Thanou, Merrill, J. T. Top
  • measures. Curr. Rheumatol. Rep. 15,
  • 2013

A randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care

  • D Jayne
  • Ann. Rheum. Dis. 72,
  • 2013

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

  • Lauwerys, R B.
  • Arthritis Rheum
  • 2013

Effects of blisibimod , a sucutaneous inhibitor of B cell activating factor , in patients with SLE

  • S. Fillatreau, D. Gray, S. Anderton, M.
  • Ann . Rheum . Dis .
  • 2013

Similar Papers

Loading similar papers…